Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: High serum levels of B-cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) have been observed in patients with idiopathic membranous nephropathy (iMN); however, their relationships with disease severity and progression remain unclear.
Methods: Patients with iMN diagnosed renal biopsy were enrolled in this study. The concentrations of BAFF and APRIL were determined using ELISA kits. Proteinuria remission, including complete remission (CR) and partial remission (PR), and renal function deterioration were defined as clinical events. The Cox proportional hazards method was used to analyze the relationship between cytokine levels and disease progression.
Results: Seventy iMN patients were enrolled in this study, with a median follow-up time of 24 months (range 6-72 months). The serum levels of BAFF and APRIL were higher in iMN patients than in healthy controls but lower than those in minimal change disease (MCD) patients. The serum BAFF level was positively correlated with the serum APRIL level, serum anti-phospholipase A2 receptor (anti-PLA2R) antibody level, and 24-h proteinuria and negatively correlated with the serum albumin (ALB) level. However, no significant correlation was observed between the serum APRIL level and clinical parameters. According to the multivariate Cox proportional hazards regression model adjusted for sex, age, systolic blood pressure (SBP), estimated glomerular filtration rate (eGFR), immunosuppressive agent use, 24-h proteinuria, APRIL level, and anti-PLA2R antibody, only the serum BAFF level was identified as an independent predictor of PR (HR, 0.613; 95% CI, 0.405-0.927; = 0.021) and CR of proteinuria (HR, 0.362; 95% CI, 0.202-0.648; < 0.001).
Conclusions: A high serum BAFF level is associated with severe clinical manifestations and poor disease progression in patients with iMN.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11328817 | PMC |
| http://dx.doi.org/10.1080/0886022X.2024.2391069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring immunological alterations of B cells in peripheral immunity via single-cell RNA sequencing: insights into primary membranous nephropathy.
Front Immunol
September 2025
Department of Nephrology, The First Affiliated Hospital with Nanjing Medical University, Nanjing Medical University, Nanjing, China.
Background: Primary Membranous Nephropathy (PMN) is characterized by dysregulated immune responses, with B cells playing critical roles in disease pathogenesis. However, the immunopathogenic mechanisms underlying B cell involvement in PMN remain elusive.
Methods: We employed single-cell RNA sequencing on peripheral blood mononuclear cell samples (PBMC) obtained from 6 patients with PMN and 3 healthy controls (NC) to explore the transformation of B cells and their interaction with immune cells.
Evaluation of Salivary and Serum BAFF and TWEAK Levels in Patients with Thalassemia Major and Gingival Inflammation: An Observational Case-Control Study.
Eur J Dent
August 2025
Department of Periodontics, College of Dentistry, University of Baghdad, Baghdad, Iraq.
Limited research has been conducted to evaluate the relationship between periodontal parameters, systemic biomarkers, and thalassemia major (TM) concerning gingival inflammation. This study aims to assess the potential association of B cell activating factor (BAFF) and tumor necrosis factor weak inducer of apoptosis (TWEAK) with periodontal parameters in patients diagnosed with TM and gingivitis, compared with their healthy counterparts.The current study involved 101 participants aged 18 to 35 years; each subject completed a preliminary assessment to ascertain their eligibility for recruitment.
View Article and Find Full Text PDFCytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis.
Ann Clin Transl Neurol
August 2025
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Objectives: To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE).
Methods: Cytokines/chemokines (IL-1-beta, IL-2, IL-4, IL-5, IL-6, IL-8/CXCL8, IL-10, IL-12p70, IL-13, IL-17A, GM-CSF, TNF-alpha, IFN-gamma, CXCL9, CXCL10, CXCL13, BAFF) and NfL concentrations were measured in CSF and paired serum from LGI1-AE patients evaluated at Mayo Clinic (01/2015-02/2024), using a multiplex immunoassay system (ELLA, Bio-Techne) and correlated with clinical outcomes. A laboratory-based cohort of LGI1-IgG-positive patients and control cohorts, including patients with mixed non-inflammatory disorders (MNID), Alzheimer's disease (AD), and temporal lobe epilepsy (TLE) were analyzed.
Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study.
Front Pharmacol
July 2025
Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: This retrospective cohort study evaluated the therapeutic efficacy and safety profile of telitacicept, a novel dual B-cell-activating factor (BAFF)/a proliferation-inducing ligand (April) inhibitor, in managing systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) and nephrotic syndrome (NS), with particular focus on renal and hematological parameters.
Methods: 12 SLE patients with biopsy-confirmed LN and NS who received weekly subcutaneous telitacicept (80/160 mg) combined with standard therapies for ≥12 months were analyzed. Primary endpoints include changes in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, 24-h urinary protein excretion (24hUpr), complement levels (Complement Component 3/Complement Component 4), anti-double-stranded DNA antibodies (anti-dsDNA) titers, immunoglobulin profiles, serum creatinine, and hemoglobin (HGB) at baseline, 3-month, and 12-month intervals.
Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease.
Hepatol Res
July 2025
Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Tsu, Japan.
Aims: Elevated serum free light chain (FLC) and B-cell activating factor (BAFF) levels have been reported to be associated with B-cell activation and to serve as biomarkers reflecting disease severity in various diseases. However, limited investigation has been conducted in the context of chronic liver disease (CLD), and the aim of this study was to clarify the clinical utility of FLC and BAFF in CLD.
Methods: Serum FLC and BAFF levels were measured in healthy individuals (HC; n = 23) and in a cohort of patients with chronic hepatitis (CH; n = 107) and liver cirrhosis (LC; n = 50) of various etiologies and the associations of κ-FLC, λ-FLC, or BAFF with liver function test results and survival rates were investigated.